Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SORD | Q00796 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 4/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10294567 | 0.83 | HRH4 (0.66) | KMT2AHRH4DRD2 | |
| SCHEMBL15386251 | 0.75 | MAPT (0.50) | MEN1KMT2AHRH4KDM4EALDH1A1 | |
| SCHEMBL11981508 | 0.70 | MEN1 (0.62) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21780751 | 0.68 | CYP2C9 (0.50) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13647731 | 0.67 | HRH4 (0.45) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL26604093 | 0.67 | ALDH1A1 (0.45) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9418612 | 0.67 | SORD (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL12903094 | 0.66 | KMT2A (0.55) | KMT2AHRH4 | |
| SCHEMBL22924659 | 0.66 | KMT2A (0.55) | KMT2AHRH4 | |
| SCHEMBL11159169 | 0.66 | MEN1 (0.60) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | NANTBIO, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | CALIFORNIA CAPITAL EQUITY, LLC (CA) | 2012-09-20 | — | — | US | disclosed |
| CN-102573485-A | Triazine derivatives and their therapeutic use | ABRAXIS BIOSCIENCE LLC | 2012-07-11 | — | — | CN | disclosed |
| CN-102573486-A | Triazine derivatives and their therapeutic use | ABRAXIS BIOSCIENCE LLC | 2012-07-11 | — | — | CN | disclosed |
| EP-2440051-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | Abraxis BioScience, LLC (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144345-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144345-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144338-A1 | TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS | ABRAXIS BIOSCIENCE, LLC (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023497-A1 | Triazine Derivatives and their Therapeutical Applications | IL5, IKZF3, CYP11B2 | MEN1 4203/4885KMT2A 2444/4885CYP3A4 221/4885 |
| US-20120238576-A1 | Triazine Derivatives and their Therapeutical Applications | SLC10A1, GLS, SLC10A2 | MEN1 3798/4885KMT2A 2859/4885CYP3A4 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.